Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

CHMP Recommends Approval of At-Home, Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2025

The EMA’s CHMP has recommended at-home administration of pertuzumab, trastuzumab and hyaluronidase combination therapy for HER2+ breast cancer.

FDA Grants Fast Track Designation to INX-315 in CCNE1-Amplified, Platinum-Resistant Ovarian Cancer

April 30th 2025

INX-315 has received FDA fast track designation for the treatment of patients with CCNE1-amplified, platinum-resistant or refractory ovarian cancer.

Testicular Cancer Awareness Month: Early Detection and Risk Assessment Pave the Way Toward Optimal Outcomes

April 30th 2025

Adam Calaway, MD, MPH, highlights the need for early detection and education in testicular cancer.

Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer

April 29th 2025

Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.

Dr Scilipoti on the Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies

April 29th 2025

Pietro Scilipoti, MD, discusses the need for better life expectancy assessment to guide prostate cancer treatment strategies.

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

April 29th 2025

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.

Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD

April 28th 2025

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.

Bria-IMT Plus Checkpoint Inhibition Is Safe and Yields Clinical Benefit in Pretreated Metastatic Breast Cancer

April 28th 2025

Bria-IMT plus checkpoint inhibition showed a manageable safety profile and activity in metastatic breast cancer.

Dr Trinh on Outcomes for Darolutamide Plus ADT in Black Patients With mHSPC

April 28th 2025

Quoc-Dien Trinh, MD, MBA, discusses outcomes for darolutamide plus ADT in Black patients with metastatic hormone-sensitive prostate cancer.

Dr Ghoreifi on the Feasibility for Consolidative Surgery After Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

April 28th 2025

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.

Ivonescimab Wins NMPA Approval in China for First-Line, PD-L1+ Advanced NSCLC

April 28th 2025

China’s NMPA approved ivonescimab for the first-line treatment of PD-L1–positive advanced non–small cell lung cancer.

Zongertinib Yields Clinical Benefit in Previously Treated, HER2-Mutated, Advanced NSCLC

April 28th 2025

Zongertinib provided clinical benefit in previously treated advanced non–small cell lung cancer harboring HER2 mutations.

Linvoseltamab Receives EC Approval for Heavily Pretreated R/R Myeloma

April 28th 2025

Linvoseltamab earned EC approval for relapsed/refractory multiple myeloma after at least 3 prior lines of therapy.

First-Line Penpulimab Plus Chemo Extends PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma

April 27th 2025

Penpulimab plus chemotherapy improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.

Neoadjuvant Mitomycin C Demonstrates Favorable Safety and Potential RFS Benefit in NMIBC

April 27th 2025

Neoadjuvant mitomycin C improved 18-month recurrence-free survival and demonstrated favorable safety in non–muscle-invasive bladder cancer.

Dr Jacob on the Potential for TAR-200 to Shift the Treatment Paradigm in NMIBC

April 27th 2025

Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.

Neoadjuvant Niraparib Fails to Produce Substantial Pathologic Responses After Radical Prostatectomy in DDR-Deficient Prostate Cancer

April 26th 2025

No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.

Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC

April 26th 2025

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.

UGN-301 Shows Early Tolerability in Recurrent Non–Muscle-Invasive Bladder Cancer

April 26th 2025

Continued evaluation of UGN-301 in patients with recurrent NMIBC is warranted.

CHMP Recommends EU Approval of Zanidatamab for HER2+ Advanced Biliary Tract Cancer

April 25th 2025

The EMA’s CHMP issued a positive opinion for zanidatamab in previously treated HER2-positive biliary tract cancer.